Video

Uranimals: Episode 1

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Welcome to the first installment of Uranimals, a video series featuring urologists and their pets brought to you by Urology Times. From a dog model to a whole farm of animals, the inaugural episode has an amazing lineup. Watch Drs. Amy Pearlman, Stacy Loeb, Michael Cookson, and Casey Dauw introduce you to their furry (and feathered!) friends.

      Related Videos
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      Endourologist discusses shared decision-making and laser lithotripsy
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Kevin Zorn, MD, on preserving ejaculation with BPH therapies
      Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
      Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
      Alexander Glaser, MD, on real-world outcomes with Aquablation
      Alexander Glaser, MD, on real-world outcomes with Aquablation
      Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
      Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
      John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
      Related Content
      Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
      December 26th 2024

      Top 10 BPH articles and videos of 2024

      Benjamin P. Saylor
      As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
      Crystal light - stock.adobe.com
      March 4th 2022

      Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results

      Janelle Hart
      Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
      February 7th 2022

      Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer

      Janelle Hart
      To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
      How appropriate use criteria for PSMA-PET imaging optimize patient care
      February 2nd 2022

      How appropriate use criteria for PSMA-PET imaging optimize patient care

      Janelle Hart
      In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
      Dr. Chee summarizes latest Optilume data in patients with urethral strictures
      November 9th 2021

      Dr. Chee summarizes latest Optilume data in patients with urethral strictures

      Urology Times staff
      "Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.
      Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer
      December 16th 2020

      Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer

      Urology Times staff
      Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.
      © 2025 MJH Life Sciences

      All rights reserved.